MTOR and breast carcinoma: Furthermore, metformin elicited less rebound upregulation of total proteins in the mTOR pathway (namely, P70 S6K, as seen in Fig. 3C) in breast cancer cells, which potentially imposes a lesser risk of emergence of drug resistance to mTOR inhibition in breast cancer treatment regimens.